uniQure NV
QURE
23.14
+0.08
+0.35%
uniQure NV
US · QURE
#2954 by market cap
Listed 1970
23.14
+0.08
+0.35%
Live - 5344 symbols - heartbeat 249s ago
· 2026-10-08 08:39
Pre-market
22.85
-1.25%
After-hours
23.07
-0.30%
Overnight
22.85
-1.25%
- Market cap
- 1.61B
- P/E (TTM)i
- -5.70
- P/Bi
- 4.95
- EPSi
- -3.46
- Div yieldi
- 0.00%
- 52W posi
- 23%
Reader sentiment
Are you bullish or bearish on QURE?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is -0.59, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -40.64% YoY
Margins
- Gross margin
- 89.53%
- Operating margin
- -1,166.77%
- Net margin
- -1,236.00%
Key ratios & quality
- Enterprise valuei
- 1.04B
- Altman Z-Scorei
- -0.59
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 11.28M | 7.28M | 37.51M | 524.00M | 106.48M | 15.84M | 27.12M | 16.10M |
| Gross profit | -- | 7.28M | 37.51M | 499.03M | 103.14M | 2.22M | 8.79M | 14.41M |
| Selling & admin expenses | 25.31M | 33.54M | 42.58M | 56.29M | 54.70M | 73.08M | 50.68M | 65.34M |
| Research & development | 74.81M | 94.74M | 122.40M | 143.55M | 197.59M | 214.86M | 143.78M | 140.67M |
| Operating profit | -86.68M | -119.11M | -124.12M | 311.49M | -144.25M | -282.49M | -182.18M | -187.83M |
| Pretax profit | -83.07M | -124.20M | -141.44M | 332.81M | -128.26M | -306.56M | -237.13M | -193.34M |
| Tax | 231.00K | 0 | -16.42M | 3.22M | -1.47M | 1.92M | 2.43M | 5.63M |
| Net profit | -83.30M | -124.20M | -125.02M | 329.59M | -126.79M | -308.48M | -239.56M | -198.97M |
| Basic EPS | -2 | -3 | -3 | 7 | -3 | -6 | -5 | -3 |
| Diluted EPS | -2.34 | -3.11 | -2.81 | 7.04 | -2.71 | -6.47 | -4.92 | -3.46 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 1.57M | 5.26M | 3.70M | 5.57M | 3.56M | 5.84M |
| Gross profit | 1.37M | 4.61M | 3.30M | 5.13M | 3.34M | 5.49M |
| Selling & admin expenses | 10.91M | 13.50M | 19.44M | 21.49M | 20.07M | 17.37M |
| Research & development | 36.14M | 35.38M | 34.37M | 34.78M | 29.18M | 33.96M |
| Operating profit | -37.37M | -42.89M | -49.49M | -51.49M | -44.27M | -44.68M |
| Pretax profit | -43.14M | -37.29M | -71.90M | -41.00M | -53.05M | -79.22M |
| Tax | 496.00K | 425.00K | 8.63M | -3.92M | 488.00K | 1.84M |
| Net profit | -43.64M | -37.72M | -80.53M | -37.09M | -53.54M | -81.06M |
| Basic EPS | -1 | -1 | -1 | -1 | -1 | -1 |
| Diluted EPS | -0.82 | -0.69 | -1.38 | -0.56 | -0.85 | -1.22 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 236.58M | 384.21M | 258.91M | 628.24M | 476.77M | 651.85M | 390.29M | 655.99M |
| Cash & ST investments | 234.90M | 377.79M | 244.93M | 556.26M | 352.84M | 617.89M | 367.52M | 622.54M |
| Inventory | -- | -- | -- | 0 | 6.92M | 12.02M | -- | -- |
| Total assets | 273.91M | 448.63M | 340.40M | 809.18M | 704.96M | 831.69M | 556.54M | 824.91M |
| Total current liabilities | 19.97M | 31.63M | 27.33M | 36.76M | 75.92M | 73.68M | 40.05M | 62.92M |
| Short-term debt | -- | 5.87M | 5.52M | 5.77M | 8.38M | 8.34M | 3.60M | 3.86M |
| Long-term debt | 35.47M | 36.06M | 35.62M | 100.96M | 102.79M | 101.75M | 51.32M | 49.70M |
| Total liabilities | 94,300,000.00 | 125,572,000.00 | 96,490,000.00 | 213,404,000.00 | 228,955,000.00 | 624,019,000.00 | 563,288,000.00 | 626,007,000.00 |
| Total equity | 179.61M | 323.06M | 243.91M | 595.78M | 476.01M | 207.67M | -6.75M | 198.90M |
| Retained earnings | -535.51M | -659.71M | -784.73M | -455.14M | -581.93M | -890.41M | -1.13B | -1.33B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 435.42M | 408.57M | 716.19M | 655.99M | 615.74M | 834.27M |
| Cash & ST investments | 409.01M | 376.97M | 694.25M | 622.54M | 586.55M | 810.34M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 605.40M | 584.89M | 888.38M | 824.91M | 778.71M | 985.10M |
| Total current liabilities | 36.31M | 40.93M | 100.63M | 62.92M | 59.20M | 83.35M |
| Short-term debt | 3.70M | 3.91M | 3.91M | 3.86M | 2.99M | 2.99M |
| Long-term debt | 51.59M | 51.84M | 51.88M | 49.70M | 49.94M | 50.15M |
| Total liabilities | 571,717,000.00 | 588,893,000.00 | 659,636,000.00 | 626,007,000.00 | 629,363,000.00 | 661,053,000.00 |
| Total equity | 33.69M | -4.00M | 228.75M | 198.90M | 149.34M | 324.05M |
| Retained earnings | -1.17B | -1.21B | -1.29B | -1.33B | -1.38B | -1.46B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -76.04M | -98.68M | -134.83M | 287.96M | -145.06M | -145.93M | -182.73M | -177.96M |
| Depreciation & amortization | 12.42M | 6.67M | 10.65M | 7.30M | 8.54M | 11.90M | 12.64M | 14.76M |
| Free cash flow | -80.28M | -105.33M | -144.31M | 270.52M | -162.75M | -153.08M | -194.42M | -178.40M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 138.36M | 242.72M | 7.44M | 33.70M | 1.45M | 308.00K | 2.12M | 391.90M |
| Ending cash balance | 237.34M | 380.73M | 247.68M | 559.35M | 231.17M | 244.54M | 160.33M | 81.80M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -44.10M | -39.90M | -16.40M | -77.57M | -38.24M | -28.58M |
| Depreciation & amortization | 4.53M | 3.63M | 3.63M | 2.97M | 2.96M | 4.91M |
| Free cash flow | -44.23M | -40.16M | -16.33M | -77.69M | -38.38M | -29.05M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 80.67M | 44.00K | 308.74M | 2.45M | 550.00K | 249.12M |
| Ending cash balance | 218.66M | 255.27M | 598.55M | 81.80M | 141.54M | 414.56M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -61.94 | -49.42 | -44.10 | 78.50 | -23.66 | -90.24 | -238.46 | -207.10 |
| ROA %i | -34.46 | -34.38 | -31.69 | 57.34 | -16.75 | -40.15 | -34.51 | -28.81 |
| ROIC %i | -51.66 | -40.17 | -34.42 | 64.35 | -17.15 | -60.55 | -102.69 | -102.96 |
| 5-year avg ROE %i | -99.79 | -76.53 | -67.14 | -36.12 | -20.12 | -25.78 | -63.59 | -96.19 |
| EBIT margin %i | -717.06 | -1,653.50 | -366.84 | 64.94 | -109.46 | -1,672.66 | -639.35 | -815.92 |
| FCF / sales %i | -- | -- | -- | 51.63 | -- | -- | -- | -- |
| Current ratioi | 11.85 | 12.15 | 9.47 | 17.09 | 6.28 | 8.85 | 9.74 | 10.43 |
| Quick ratioi | 11.77 | 11.97 | 9.20 | 16.73 | 6.00 | 8.44 | 9.32 | 9.99 |
| Debt / assetsi | 12.95 | 16.29 | 21.02 | 16.77 | 20.27 | 16.64 | 11.87 | 7.68 |
| LT debt / equityi | 19.75 | 20.80 | 27.07 | 21.81 | 28.26 | 62.63 | -- | 29.93 |
| Interest coveragei | -37.46 | -31.60 | -35.98 | 45.53 | -9.96 | -6.38 | -2.72 | -2.12 |
| Revenue CAGR (3Y) %i | 2.18 | -33.80 | 41.98 | 259.44 | 144.55 | -24.97 | -62.73 | -46.73 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -241.16 | -427.47 | -165.27 | -207.10 | -228.24 | -157.61 |
| ROA %i | -31.64 | -30.25 | -30.65 | -28.81 | -30.18 | -32.13 |
| ROIC %i | -96.49 | -118.78 | -95.78 | -102.96 | -117.21 | -101.50 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -755.18 | -942.05 | -1,031.34 | -815.92 | -786.66 | -993.35 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 11.99 | 9.98 | 7.12 | 10.43 | 10.40 | 10.01 |
| Quick ratioi | 11.33 | 9.35 | 6.94 | 9.99 | 9.97 | 9.79 |
| Debt / assetsi | 10.93 | 11.40 | 7.45 | 7.68 | 8.13 | 6.38 |
| LT debt / equityi | 185.53 | -- | 27.21 | 29.93 | 40.40 | 18.47 |
| Interest coveragei | -2.43 | -2.17 | -2.61 | -2.12 | -2.34 | -3.11 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Pipeline of innovative gene therapies seeking to deliver to patients suffering from rare and other100.00%
Quote time 2026-10-08 08:39:35 · For reference only, not investment advice and not tailored to your situation.